<i>Nmnat2</i> deficiency in the arcuate nucleus or paraventricular nucleus induces <i>Sarm</i> 1‐independent neuron loss and liraglutide‐reversible obesity
Nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2) plays an important role in maintaining axon integrity, and the arcuate nucleus (ARC), and paraventricular nucleus (PVN) are crucial nuclei in the control of energy balance. However, the effect of Nmnat2 deficiency in ARC and PVN is still unclear. Nmnat2 <sup>loxP/loxP</sup> or Nmnat2 <sup>loxP/loxP</sup> , Sarm1 <sup>-/-</sup> mice were bilaterally injected with AAV-CMV-GFP-Cre once into the ARC, PVN, or lateral parabrachial nucleus (LPBN) to obtain Nmnat2 <sup>ARC-/-</sup> , Nmnat2 <sup>PVN-/-</sup> , Nmnat2 <sup>LPBN-/-</sup> , Nmnat2 <sup>ARC-/-</sup> , SKO, Nmnat2 <sup>PVN-/-</sup> , SKO, or Nmnat2 <sup>LPBN-/-</sup> , SKO mice. Syn1-Cre mice were bilaterally injected with AAV-EF1a-flex-taCasp3-TEVp once into the ARC or PVN to specifically induce neuron loss. Metabolic changes were measured in the mice intraperitoneally injected with or without liraglutide, a glucagon-like peptide-1 (GLP-1) analog. Neuron loss and neuron activation were monitored by immunofluorescence. Deletion of Nmnat2 in ARC or PVN of mice leads to neuron loss, increased food intake, and obesity in a Sarm1-independent manner. Intraperitoneal injection of liraglutide activates neurons in PVN and LPBN, and attenuates hyperphagia and obesity induced by Nmnat2 deletion or apoptosis of Syn1-positive neurons in ARC or PVN, but has no significant effect on neuron loss. Nmnat2 deficiency in LPBN leads to death within 2 weeks, which can be markedly rescued by Sarm1 deficiency. These data show that deletion of Nmnat2 in ARC or PVN in adult mice leads to Sarm1-independent neuron loss, and liraglutide-reversible hyperphagia and obesity. These findings also elucidate the integrated role of ARC or PVN for downregulating food intake, the requirement of LPBN for survival, and the ARC- or PVN-independent effect of GLP-1 on food intake.
Authors
- Z. A. Liu
- Qiwei Zhai (ORCID: https://orcid.org/0000-0002-9617-7403)
- Hejin Lai (ORCID: https://orcid.org/0000-0001-9036-872X)
- Yalan Cheng (ORCID: https://orcid.org/0000-0003-4126-2528)
- Wuling Zhong (ORCID: https://orcid.org/0000-0003-3589-3390)
- Zhishui He
- Peidong Gao (ORCID: https://orcid.org/0009-0004-1467-7570)
- Yumo Han
- Yingqi Wang (ORCID: https://orcid.org/0009-0000-9480-7179)
- Zhentong Zhang (ORCID: https://orcid.org/0000-0003-0175-3576)
- Huimin Yu (ORCID: https://orcid.org/0009-0009-4152-3063)
- Ning Feng (ORCID: https://orcid.org/0000-0002-4830-7445)
- Rui Huang (ORCID: https://orcid.org/0000-0003-3664-2905)
- Cong Zhang (ORCID: https://orcid.org/0000-0002-0952-2441)
- Z H Shen
- Jieya Dong
Institutions
- ShanghaiTech University (CN)
- Shanghai Institute of Nutrition and Health (CN)
- University of Chinese Academy of Sciences (CN)
- University of Pennsylvania (US)
Publication Details
- Journal
- The FASEB Journal
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1096/fj.202402546r
- Citations
- 1
- Primary Topic
- Nuclear Receptors and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- National Natural Science Foundation of China
- Shanghai Rising-Star Program
- National Key Research and Development Program of China